Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2
TMO
FY2025 Q4
Improving
Thermo Fisher Scientific Inc earnings call
Buzzberg read
2026 guidance assumes 3-4% organic growth and 6-8% EPS growth
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
Buzzberg read 2026 guidance assumes 3-4% organic growth and 6-8% EPS growth Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance. Read full analysisCollapse analysis
Thermo Fisher reported a strong Q4 2025 with 7% revenue growth and 8% EPS growth, beating its own guidance. Management guided 2026 to 4-6% reported revenue growth and 6-8% EPS growth, assuming stable end markets and continued share gains. Key cross-company signals included a Bayer companion diagnostic win, partnerships with OpenAI and NVIDIA, and acquisitions from Solventum and Sanofi, while highlighting tight sterile fill-finish capacity and strong bioproduction demand. Q4 revenue $12.21B (+7% YoY), adjusted EPS $6.57 (+8%), both ahead of guidance.
- 2026 guidance: revenue $46.3-47.2B (4-6% reported), adjusted EPS $24.22-24.80 (6-8% growth), organic growth 3-4%.
- Biopharma end-market grew mid-single digits full-year; bioproduction and clinical research drove results.
- Bayer companion diagnostic approval and collaborations with OpenAI, NVIDIA highlight innovation partnerships.
Revenue$12.215B+10% QoQ
EPS$6.57+13% QoQ
Gross margin37.95%Reported
Operating margin18.85%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
M&A
Clario acquisition expected to close mid-2026, accretive to EPS
Demand
Biotech funding improving, but spending lags by six months
Show 3 more callouts
Guidance
Q1 2026 organic growth expected a few points below full year
Margins
2025 tariffs and FX headwind over 100 bps to margins
Innovation
R&D investments focused on high-impact innovation
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $12.215B | +10% QoQ |
| EPS | $6.57 | +13% QoQ |
| Gross margin | 37.95% | Reported |
| Operating margin | 18.85% | Reported |
| Free cash flow | $2.992B | Reported |
| Capex | $0.465B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $24.22–$24.80 | $24.51 | Initiated |
| Free cash flow | FY2026 | $6.8B–$7.3B | $7.05B | Initiated |
| Revenue | FY2026 | $46.3B–$47.2B | $46.75B | Initiated |
AI, capex & demand read
Management read
Confident
Management expressed confidence in execution and growth strategy, noted strong customer sentiment and innovation momentum, and reaffirmed guidance.
Management AI read
Management is integrating AI into operations and products, with a strategic collaboration with OpenAI to embed AI capabilities and improve productivity, and an NVIDIA collaboration for analytical instruments.
Investment and capacity
Net capital expenditures are expected to increase to $1.8-2.0 billion in 2026, driven by investments in U.S. manufacturing.
all 7 named companies below
Companiesreturns since call
Customers
Customers
Mark Casper
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
Evidence
“this technology received another FDA approval, this time as a companion diagnostic for Bayer's new therapy targeted for certain patients with non-small cell lung cancer.”
Partners
OPENAI
Partners
Mark Casper
Thermo Fisher is partnering with OpenAI to embed AI across its products and operations, potentially accelerating drug development and improving productivity—a positive signal for OpenAI's enterprise adoption in life sciences.
Evidence
“announced a strategic collaboration with OpenAI aimed at increasing our use of artificial intelligence at the company.”
Partners
Mark Casper
Thermo Fisher's collaboration with NVIDIA leverages AI in analytical instruments and microscopy, positioning NVIDIA's chips in high-end scientific computing applications.
Evidence
“announced an interesting collaboration with NVIDIA at the beginning of the year.”
Supply chain
Supply chain
Mark Casper
Thermo Fisher acquired Solventum's filtration and separation business to extend bioproduction capabilities; Solventum divests a non-core unit for cash.
Evidence
“completed the acquisition of our filtration and separation business from Solventum.”
Supply chain
Mark Casper
Thermo Fisher acquires a sterile fill-finish plant from Sanofi, boosting its CDMO capacity; Sanofi monetizes a site while outsourcing fill-finish capacity.
Evidence
“expanded our U.S. drug product manufacturing footprint through the acquisition of Sanofi's state-of-the-art sterile fill finish site in New Jersey.”
Supply chain
Mark Casper
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media. — Ongoing bioprocessing demand suggests peer companies in biologics manufacturing supplies (Danaher, Sartorius) may also see tailwinds.
Evidence
“Performance in the quarter was led by continued strong growth in our bioproduction business”
External signals
Supply-chain alpha · 2returns since call
Sterile fill-finish capacity is tight, driving Thermo Fisher to acquire Sanofi's site and win reshoring contracts, indicating supply constraints for drug manufacturers.
Evidence
“sterile full finish has been the area where there is heightened demand relative to industry capacity”
Thermo Fisher's bioproduction business delivered 'excellent growth' for another quarter, signaling sustained demand for single-use technologies and cell culture media.
Methodology & coverage
Management-only analysis. All 7 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.